摘要
目前,非小细胞肺癌(non-small-cell lung cancer,NSCLC)已成为癌症相关死亡的首要原因。血管生成(angiogenesis),即新生血管形成,是一个严格而复杂的调控过程,可促进肺癌及其它恶性肿瘤疾病进展和远处转移。抗血管生成治疗(anti-angiogenic therapy)是以新生血管为靶点的抗肿瘤方法。目前临床上常用的细胞毒药物作用于所有快速分裂的细胞,可导致严重治疗副作用如免疫抑制、胃肠道反应和脱发等。而除子宫内膜外新生血管形成很少发生于健康成年人,因此相对而言,抗血管生成治疗理论上副作用较少,在临床上应用具有良好的前景。由于不同个体发生的肿瘤其血管生成可能是由不同的血管生成因子调控,因此,在抗血管生成药物越来越多的今天,正确地选择患者个体,选择有针对性的治疗非常重要。本文回顾了非小细胞肺癌抗血管生成药物的预测及预后指标的临床研究及相关指标基本原理的临床前研究。
Non-small cell lung cancer （NSCLC） is currently the leading cause of cancer-related deaths worldwide. Angiogenesis, the formation of new vasculature, is a complex and strictly regulated process that promotes metastasis and disease progression in lung cancer and other malignancies. Anti-angiogenic therapy is an anti-cancer strategy that targets the new vessels. Most anti-cancer agents used in the clinic include cytotoxic drugs, which target all rapidly dividing cells, resulting in severe adverse effects. These effects in- clude immunosuppression, intestinal problems, and hair loss. By contrast, anti-angiogenic agents theoretically exhibit fewer side effects because angiogenesis rarely occurs in healthy adults, except in the uterine endometrium. Various angiogenic factors may contribute to the regulation of angiogenesis in the individual tumor; thus, the proper selection of patients who may benefit from a specific therapy is important, considering the increasing number of clinically tested agents. This study provides an overview of angiogenic molecules cur- rently being investigated as prognostic and predictive biomarkers in NSCLC. Clinical examples are presented to show the rationales for investigating various biomarkers of pre-clinical studies.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2014年第1期83-86,共4页
Chinese Journal of Clinical Oncology
基金
supported by China International Medical Foundation(No.CIMF-F-H001-042)
关键词
非小细胞肺癌
抗血管生成治疗
生物指标
non-small cell lung cancer, anti-angiogenic therapy, biomarkers
